Gardner Lewis Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Gardner Lewis Asset Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-522	Closed	-$549K	–	81
2024 Q3	$549K	Buy	+522	New	+$581K	0.15%	63
2023 Q1	–	Sell	-1,949	Closed	-$1.41M	–	85
2022 Q4	$1.41M	Buy	1,949 +346	+22%	+$255K	0.48%	47
2022 Q3	$1.1M	Buy	+1,603	New	+$1.01M	0.24%	65
2019 Q2	–	Sell	-3,866	Closed	-$1.59M	–	89
2019 Q1	$1.59M	Buy	+3,866	New	+$1.59M	0.2%	63
2017 Q3	–	Sell	-3,335	Closed	-$1.64M	–	109
2017 Q2	$1.64M	Buy	+3,335	New	+$1.46M	0.11%	84

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Gardner Lewis Asset Management's REGN Position: Q4 2024 in Review

Gardner Lewis Asset Management sold out of Regeneron Pharmaceuticals (REGN) in Q4 2024, closing a stake of 522 shares — an estimated $549K sold.

Gardner Lewis Asset Management first reported a position in REGN in Q2 2017 and held it in 5 quarters. The position peaked at $1.64M in Q2 2017. 1,320 funds tracked by Wall St. Rank hold REGN as of Q4 2024.

Gardner Lewis Asset Management reported no remaining Regeneron Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Gardner Lewis Asset Management sold 522 Regeneron Pharmaceuticals shares in Q4 2024, an estimated $549K.
Gardner Lewis Asset Management first reported a position in Regeneron Pharmaceuticals in Q2 2017 and held it in 5 quarters.
Gardner Lewis Asset Management's Regeneron Pharmaceuticals position peaked at $1.64M in Q2 2017.
1,320 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2024.

Based on Gardner Lewis Asset Management's 13F filing for Q4 2024, filed 12 Feb 2025.